Be Prepared, FDA to Hand Down Approval Decision for ACelRx Next Month
Research - AcelRx (ACRX) will receive an approval decision form the US FDA next month for Zalviso. Read more, and understand our point of view, here.
PremiumMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Auxilium and QLT Inc: Astute Investors Saw the Exit Coming
Insights - Driven by Canada’s lower corporate tax rate, Auxilium Pharmaceuticals (AUXL) plans to merge with QLT Inc. (QLTI), a small Canadian biotechnology company that essentially put … Continue Reading
Read now
Vertex: The Biggest Biotech Event of 2014 Goes the Right Way
Insights - Shares of Vertex Pharmaceuticals (VRTX) are up 50% to $100 following success in two phase 3 studies of a cystic fibrosis drug combination that could be worth north … Continue Reading
Read now
Ohr Calls Drug Analysis ‘Positive’ but Misses Primary Goal
Insights - Ohr Pharmaceutical (OHRP) on Tuesday released interim results from a phase 2 study of its Squalamine eye drops in Wet Age-related Macular Degeneration (AMD). Squalamine eye drops, … Continue Reading
Read now
Investors Should Celebrate as Shire Goes Up Against AbbVie
Insights - The rejected bid is forcing Shire (SHPG) execs to issue longterm guidance, an uncommon practice in bio, and similar to what's going on at Allergan (AGN)
Read now
Panic-Buyers are Making Out As Biotech Recovers
Recap - The “Hold Your Nose, Buy the Panic” crowd is being vindicated as biotech recovers from a 2-month correction, and makes its way towards old highs. … Continue Reading
Read nowAbbVie’s Unwelcome Advances Rebuffed by Shire
Insights - Shire Plc (SHPG) confirmed before the open on Friday said that it has rejected a $46 billion bid from AbbVie (ABBV), which represented a 25% premium … Continue Reading
Read now